...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Japanese publication response from IR

This is the response i got from Clayton, take what you want from it or what it actual means

Hello xxxxxx,

Thank you for your email.

I refer you to slide 15 in the latest Zenith PRESENTATION for accurate information on the clinical development plans at Zenith. As you will see, any future trials are not expected until sometime mid-2017 2017 and no guidance has been provided by the company in that regard.

With respect to the link to the Japanese website. I would consider this speculation at best and therefore am not permitted to comment on its content.

If there were material developments, the company would be obligated under continuous and timely disclosure requirements to announce them.

I trust this addresses your concerns.

Kind regards,

Clayton

Share
New Message
Please login to post a reply